<DOC>
	<DOCNO>NCT01836692</DOCNO>
	<brief_summary>This study patient course chest radiotherapy treatment receive chemotherapy treatment non-small cell lung cancer . Patients non-small cell lung cancer risk tumour lung recur progress treatment . In study , investigate : - whether give target individualised type chest irradiation radiotherapy lung tumour ( know Isotoxic IMRT ) , practical whether cause side effect tolerate - whether new method deliver radiotherapy reduce risk tumour lung recur progress - whether survival improve use new radiotherapy method The dose chest irradiation calculate specifically suit patient 's body shape , position lung cancer , close healthy tissue tumour . Radiotherapy deliver twice day maximum period 4.5 week . The duration treatment vary individually accord deliver dose tumour area .</brief_summary>
	<brief_title>Isotoxic Intensity Modulated Radiotherapy ( IMRT ) Stage III Non Small Cell Lung Cancer ( NSCLC ) - A Feasibility Study</brief_title>
	<detailed_description>Background : Approximately 12,000 patient diagnosed stage III NSCLC UK year survival ~15 % 5 year . As majority patient suitable gold standard treatment ( concurrent chemo-radiotherapy ( CTRT ) , novel strategy integrate radiotherapy ( RT ) technological advance radiobiological knowledge need evaluate patient treat alternative treatment option , sequential CTRT . There solid evidence improve local control lung cancer lead increase survival . Strategies improve local control stage III NSCLC include dose escalation individualisation limit dose deliver surround normal tissue . We hypothesise facilitate use IMRT . Objectives : To demonstrate feasibility deliver isotoxic RT use IMRT hyperfractionated accelerated RT stage III NSCLC patient suitable concurrent CTRT . Endpoints : Primary endpoint : Delivery isotoxic IMRT dose &gt; 60 Gy EQD2 ( total biologically equivalent 2 Gy fraction ) . Secondary endpoint : Estimation suitability lung isotoxic IMRT , estimation proportion patient acute grade 3+ non haematological toxicity , estimation late toxicity , estimation local control/overall survival development robust Quality Assurance ( QA ) process lung IMRT . Design : Prospective multicentre , non-randomised feasibility study early stopping rule . 35 patient recruit prospective multicentre feasibility study . Stopping rule place ensure safety patient . We estimate regimen would add value national randomise phase II trial 80 % patient plan dose &gt; 60 Gy EQD2 . Intervention : Patients stage III NSCLC , PS 0-2 , suitable concurrent CTRT , treat individualised dos radiation base pre-specified normal tissue dos ( spinal cord , brachial plexus , lung tissue , heart great vessels/proximal bronchial tree ) . Radiotherapy deliver twice-daily maximum period 4.5 week use IMRT dose radiation increase one organ risk tolerance maximum dose 79.2 Gy reach .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically cytologically confirm NSCLC Inoperable Stage III disease ( T3N13 , T4 , N2 3 ) confirm PET scanning , mediastinoscopy thoracoscopy Patients treat least 2 cycle platinum base induction chemotherapy able start radiotherapy within 5 week last cycle chemotherapy Tumour judge inoperable lung MDT Age 18+ , upper age limit Performance status ( PS ) ECOG 02 . Patients PS 2 whose general condition explain disease include discretion local investigator . Patients PS 2 result comorbid condition exclude Patient consider suitable radical RT Tumour encompass within radical RT treatment volume ( MLD expect &lt; 20Gy ) Patients suitable standard concurrent CTRT Patients suitable radical RT due PS comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>